|
|
 |
|
Viewing report
|
|
|
|
Niche Cancers 2001: Melanoma
Datamonitor, June 2001
As an indication that remains largely unresponsive to the majority existing pharmacologicalbased therapies, there is substantial commercial opportunity for pipeline agents that offer even moderate improvements in efficacy. However, in the short-term, drugs that demonstrate impressive toxicity and dosing, which thereby enhance quality of life, are expected to achieve significant commercial success, until, at least, more efficacious agents reach the market.
Customers who bought this item also bought
Strategic Perspectives: Malignant Melanoma - Biotechnology-Driven Agents Finding a Flagship Indication?
Drugs of Tomorrow: Cancer Overview - The synergistic advance: innovatives compliment traditional chemotherapies
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Drugs of Tomorrow: Cancer Overview
Molecular Diagnostics - Global Strategic Business Report
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies - More Drugs on the Market, More Targets in the Pipeline
|
|
|
|
